<DOC>
	<DOCNO>NCT03034538</DOCNO>
	<brief_summary>In 12-week , open-label pilot study , investigator enroll 20 subject Parkinson 's Disease determine two dos Zonisamide tolerable demonstrate clinical benefit Dyskinesias . The primary outcome measure tolerability , determine number subject able complete study originally assign dosage . Secondary outcome measure use Unified Dyskinesia Rating Scale ( UDysRS ) , comprise Objective Section Historical Section , compare baseline 6 12-week measurement . Additional analysis effect Zonisamide quality life measure Parkinson 's Disease Quality Life Questionnaire ( PDQ-39 ) .</brief_summary>
	<brief_title>An Open-Label Tolerability Exploratory Efficacy Study Zonisamide Dyskinesias Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>Diagnosis PD Identified dyskinesia limb trunk agree upon subject investigator , dyskinesia consider moderately completely disable ( UPDRS question 33 , great equal 2 ) Able provide inform consent swallow capsule Stable dos dopaminergic therapy 2 week expect throughout study . Atypical parkinsonism Concurrent use amantadine active DBS patient control settings Prior surgery PD Sulfa allergy intolerance zonisamide Significant concomitant medical illness opinion Principal Investigator ( renal disease , liver disease ) Pregnant subject subject plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>